NSE · SATKARTAR
Sat Kartar Life Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹203 Cr with net profit ₹17 Cr — a 8.42% net margin, versus 6% the period before.
Shareholding
As of 2026-03-31
- Promoter63.62%
- Public34%
- FII0.13%
- DII2.26%
846 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.99× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #1 of 50 by market cap · medians across 44 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,83,052 Cr | 82.04 | 21.77 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹46,642 Cr | 40.71 | 4.5 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,847 Cr | 38.64 | 9.66 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,245 Cr | 101.48 | 22.69 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹19,634 Cr | 29.51 | 5.83 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹18,151 Cr | 63.83 | 7 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹18,060 Cr | 27.49 | 4.63 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹14,340 Cr | 27.76 | 4.74 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,236 Cr | 52.55 | 6.06 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,341 Cr | 50.18 | 6.79 | 12.36% | 18.59% |
| Sat Kartar Life Limited(this company) | — | 13.07 | 3.33 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashSat Kartar Life Limited operates in the Pharmaceuticals sector. The company has a Price-to-Earnings ratio of 12.78 and an EPS of 10.96. Its book value stands at 42.97. The debt-to-equity ratio is 0.13, and the ROCE is 39.92%.
Positives
- +The debt-to-equity ratio is low at 0.13, indicating limited reliance on borrowed capital.
- +The Return on Capital Employed (ROCE) is 39.92%, suggesting efficient use of capital.
- +Promoter holding is high at 63.62% as of Mar 2026.
- +Promoter shares pledged are 0%, indicating no promoter shares are pledged.
Negatives
- −No quarterly results have been disclosed in the provided data.
- −The company is currently under ESM Stage 1 surveillance.
- −FII shareholding decreased from 6.76% in Jan 2025 to 0.13% in Mar 2026.
- −Net profit decreased from Rs 6.31 Cr in Mar 2024 to Rs 9.81 Cr in Mar 2025, from a peak of Rs 6.3055 Cr in Mar 2024 to Rs 9.815 Cr in Mar 2025.
Financial performance
Sat Kartar Life Limited's revenue increased from Rs 52.31 Cr in Mar 2022 to Rs 163.68 Cr in Mar 2025. Net profit also saw a rise, from Rs 1.39 Cr in Mar 2022 to Rs 9.81 Cr by Mar 2025. Earnings Per Share (EPS) grew from Rs 1.98 in Mar 2022 to Rs 7.37 in Mar 2025.
Profitability & returns
The company's ROCE is 39.92%. EPS has grown from Rs 1.98 in Mar 2022 to Rs 7.37 in Mar 2025. This indicates an upward trend in the company's ability to generate returns from its capital employed.
Balance sheet
Sat Kartar Life Limited has a debt-to-equity ratio of 0.13, indicating a low reliance on debt for financing. The book value per share is Rs 42.97.
Ownership & pledges
There are no pledged promoter shares as of Mar 2026. The number of shareholders was 846 in Mar 2026.
Regulatory & surveillance
Sat Kartar Life Limited is under ESM Stage 1 surveillance, which includes measures for enhanced monitoring of the company's trading activity.
Data as of — price: 2026-09-17 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.